Volume 28, Number 6—June 2022
Research
Economic Burden of Reported Lyme Disease in High-Incidence Areas, United States, 2014–2016
Table 5
Societal perspective of total cost of Lyme disease per participant, by disease category, in high-incidence areas, United States, 2014–2016
Disease category |
No. participants |
Societal perspective, total cost per participant,* 2016 US dollars |
|||||
Median |
Mean |
SD |
10th percentile |
90th percentile |
Range |
||
All† | 613 | 690 | 2,032 | 6,091 | 203 | 4,201 | 54–122,766 |
Confirmed localized | 273 | 493 | 1,307 | 3,559 | 154 | 2,678 | 54–18,322 |
Confirmed disseminated | 154 | 1,081 | 3,251 | 20,908 | 297 | 6,238 | 216–122,766 |
Probable | 186 | 940 | 2,620 | 15,533 | 316 | 5,021 | 130–105,500 |
*Total cost per participant according to the societal perspective includes societal medical costs, patient nonmedical costs, and cost of productivity losses. Patient medical costs were not added because they are already included in societal medical costs. †Estimates for the overall population use the sample-weighted data except the range.